Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets

Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger

Aarti Pharmalabs Limited has announced that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs Limited the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger.

The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs Limited’s dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy efficient initiatives across its operations, and active engagement with its value chain partners.

"We are excited to embark on this next phase of our sustainability journey and are confident that by working together, we can make a meaningful difference," said Hetal Gogri Gala, Vice Chairperson and Managing Director, Aarti Pharmalabs.

"This approval is a testament to our unwavering commitment to building a sustainable future and reflects the collective dedication of our entire team. We recognize the urgent need for climate action, and these targets provide a clear roadmap for reducing our environmental impact in line with global climate goals," said Narendra J. Salvi, Managing Director, Aarti Pharmalabs.

"This is more than just a milestone; it is a reaffirmation of our purpose to operate responsibly and contribute to a greener, more resilient future," added Tanaji S. Shinde, Head of Sustainability, Aarti Pharmalabs.